Telix Pharmaceuticals Limited (ASX:TLX) saw its shares surge 5.04% during intraday trading on Friday, as the biopharmaceutical company attracted investor attention following positive analysis of its growth trajectory and recent strategic moves.

The company, which specializes in therapeutic and diagnostic radiopharmaceuticals, is forecasted to achieve annual earnings growth of 40.05% and revenue growth of 13.1% per year, significantly outpacing the Australian market average. This robust growth outlook is supported by recent strategic initiatives, including a collaboration with United Imaging Healthcare North America Inc. to enhance theranostic solutions in the U.S. market.

Further bolstering investor confidence, recent insider trading activity shows more shares were bought than sold, indicating management's belief in the company's future prospects. Analysis suggests Telix Pharmaceuticals' current share price may be undervalued compared to its estimated fair value, contributing to the buying interest during the trading session.